Back to Crohns Disease And Colitis

NCT03599622

NCT03599622
Terminated Phase 2 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with Crohn's Disease for at least 3 months before the screening visit, affecting the small intestine, large intestine, or both
  • You have tried one or more standard treatments for Crohn's Disease but they did not work well enough, stopped working, or you could not tolerate them
  • Your Crohn's Disease is currently active and considered moderate to severe
  • If applicable, you are willing to use specific methods of birth control during the trial (both men and women)

Who may not be able to join:

  • Your colitis is very severe or rapidly worsening in a way that is likely to need surgery or a hospital stay
  • You have been diagnosed with another type of colitis (such as ulcerative colitis, an infection-related colitis, or others) instead of, or alongside, Crohn's Disease
  • You have previously taken the study drug (BMS-986165) in any other study
  • You have a serious illness or an unstable health condition affecting organs such as the kidneys, liver, lungs, or mental health, or you have an active infection that the trial doctor believes would put you at significant risk

Please note: There may be additional eligibility requirements not listed here.


Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Terminated
Phase
Phase 2
Sponsor
Bristol-Myers Squibb
Registry
clinicaltrials_gov
Start date
16 July 2018
Est. completion
12 December 2022

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇳 China 🇨🇿 Czechia 🇩🇰 Denmark 🇫🇷 France 🇩🇪 Germany 🇭🇺 Hungary 🇮🇪 Ireland 🇮🇱 Israel 🇮🇹 Italy 🇯🇵 Japan 🇲🇽 Mexico 🇳🇱 Netherlands 🇵🇱 Poland 🇵🇹 Portugal 🇷🇴 Romania 🇷🇺 Russia 🇰🇷 South Korea 🇪🇸 Spain 🇨🇭 Switzerland 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

9 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Percent of Participants Achieving Clinical Remission at Week 12; Percent of Participants Achieving Endoscopic Response at Week 12

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov